SGO's Statement on Use of CA125 for Monitoring Ovarian Cancer


Last weekend a European study regarding the use of CA 125 testing in ovarian cancer patients was presented at the American Society of Clinical Oncologists (ASCO) Annual Meeting. The study’s results indicate that women with relapsed ovarian cancer did not live longer if chemotherapy was started earlier based on a rising CA 125, as opposed to delaying treatment until symptoms developed.  The study has subsequently been covered by a variety of professional and consumer media outlets, some of which your patients may have read.

SGO has developed a position statement regarding this study and its results in order to help you understand the study, and to assist medical professionals in answering any questions.

Posted on in Research